Healthcare Realty Trust Incorporated Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Healthcare Realty Trust Incorporated Common Stock trades at $17 (market cap $5.90B), while Vertex Pharmaceuticals Incorporated trades at $503 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.8× Healthcare Realty Trust Incorporated Common Stock's market cap, and Healthcare Realty Trust Incorporated Common Stock pays a 5.57% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Healthcare Realty Trust Incorporated Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HR | VRTX | |
|---|---|---|
Market Cap | $5.90B | $122.98B |
Volume | 4,466,610 | 1,155,743 |
Sector | Real Estate | Health |
52-Week High | $21.87 | $557.96 |
52-Week Low | $16.34 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $10.29B | $117.11B |
Dividend Yield | 5.57% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Healthcare Realty Trust Incorporated is a real estate investment trust that owns and manages outpatient medical facilities and on-campus medical office buildings across US, leasing space to physician groups, hospitals, and health systems.
Read more on HR →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →